

INDEX

Note: Page numbers of article titles are in **boldface** type.

- N-Acetyl cysteine, in hepatitis C, 484
- Acquired immunodeficiency syndrome.
See *Human immunodeficiency virus infection*.
- Adhesion molecules, in liver, 364
- Aflatoxin, hepatitis B and, 255–256
- AIDS. See *Human immunodeficiency virus infection*.
- Alanine aminotransferase, in hepatitis B, in interferon therapy, 467–473
in hepatitis C, in interferon therapy, 476–481
- Alcohol, hepatitis B virus interactions with, 255, **273–287**, **289–306**
animal studies of, 293–295
apoptosis and, 299–301
carcinogenic effects of, 278–280, 402
cytokines and, 295–297
dietary influences on, 292
mechanisms of, 275–276
prevalence of, 274
regeneration inhibition in, 293–299
serologic patterns in, 276–278
signal transduction alterations in, 293
hepatitis C virus interactions with, 264–265, **273–287**, **289–306**
animal studies of, 293–295
apoptosis and, 299–301
carcinogenic effects of, 280–281, 402–403
cytokines and, 295–297
dietary influences on, 292
mechanisms of, 275–276
prevalence of, 274
regeneration inhibition in, 293–299
serologic patterns in, 278
signal transduction alterations in, 293
hepatitis D and, 258, 460
in hepatocellular carcinoma, 378, 386–390
chemical carcinogen interactions in, 386–388
hepatitis virus interactions in, 388–390
metabolism of, in liver, 275, 292
- Alcoholic liver disease, fibrogenesis in, 371
- Animal models, for hepatocellular injury, in hepatitis, 309–310
- Antibodies, to hepatitis viral antigens. See specific viruses.
- Antigens, of hepatitis viruses. See specific viruses.
- Apoptosis, of liver cells, alcohol effects on, 299–301
- Asians, hepatitis B in, interferon in, 471–472
- Balloon cell degeneration, in liver disease, 290
- Blood products, hepatitis C in, 260–261
- Boosters, for hepatitis B vaccine, 496
- Caat enhancer binding protein, in liver regeneration, 345–347
- Cancer, liver. See *Hepatocellular carcinoma*.
- Carcinogens, chemical, in hepatocellular carcinoma. See *Hepatocellular carcinoma*.
hepatitis B virus as, 395–400, 494–495
hepatitis C virus as, 400–401, 494–495
- Carcinoma, hepatocellular. See *Hepatocellular carcinoma*.
- Carriers, of hepatitis B, therapeutic vaccines for, 501
of hepatitis C, therapeutic vaccines for, 501
- Chemical carcinogens, in hepatocellular carcinoma. See *Hepatocellular carcinoma*.
- Choline deficiency, in alcohol abuse, hepatocellular sensitivity to, 292
- Cirrhosis, as fibrogenesis sequelae, 371
hepatocellular carcinoma in, 378

- Cirrhosis (*Continued*)
 in hepatitis B, 255, 273–274
 interferon in, 471
 malignant transformation of, 399, 402
 in hepatitis C, 273–274
 malignant transformation of, 401–403
 in hepatitis D, 258, 456–457
 liver regeneration in, 355
 prevention of, hepatitis vaccines for, 493–505
- Clofibrate, in hepatocellular carcinoma, 383
- Collagens, in liver, 361–362
 gene expression regulation in, 370–371
- Colony-stimulating factors, in hepatic fibrogenesis, 367–368
- Corticosteroids, in hepatic fibrogenesis inhibition, 368
- Cryoglobulinemia, mixed, in hepatitis C, treatment of, 481–482
- Cytokines, in alcohol consumption, 275–276
 liver regeneration and, 295–297
 in liver regeneration, 328–333, 352–354
- Cytopathic effect, in hepatocellular injury, in hepatitis, 308, 317
- Delta hepatitis. See *Hepatitis D*.
- Diet, in alcohol abuse, hepatocellular sensitivity to, 292
- Elastin, in liver, 362
- Endotoxin, in alcohol consumption, liver regeneration and, 297
- Entactin, in liver, 362–363
- Enzyme immunoassay, for hepatitis C virus, 259
- Epidemiology, of viral hepatitis, 251–271
 hepatitis B, 251–256
 hepatitis C, 258–265
 hepatitis D, 256–258
- Epithelial cells, hepatic, in liver regeneration, 326–328
- Ethanol. See *Alcohol*.
- Extracellular matrix, hepatic, components of, 361–364
 degradation of, 365
 enhanced production of, 364–365
 homeostasis of, 364–365
 in liver regeneration, 333–334
 regulatory signals in, 367–368
- Famcyclovir, in hepatitis B, 474
- Fialuridine, in hepatitis B, 475
- Fibrillin, in liver, 362
- Fibrogenesis, hepatic, 361–375
 augmenters of, 367–368
 cell types involved in, 366–367
 collagen gene expression and, 370–371
 extracellular matrix enhanced production in, 364–365
 in alcoholic liver disease, 371
 in viral hepatitis, 371–372
 inhibitors of, 368
 sequelae of, 371
 stellate cell proliferation in, 368–370
 versus extracellular matrix degeneration, 365–366
 versus normal extracellular matrix, 361–364
- Fibronectin, in liver, 362
- Fibrosing cholestatic hepatitis, hepatitis B virus variants in, 420
- Flaviviruses, hepatitis C virus as, 258
- Fulminant hepatitis, hepatitis B virus variants in, 419–420
- Gancyclovir, in hepatitis B, 473–474
- Genes, of hepatitis viruses. See under specific virus.
- Genotoxic carcinogens, in hepatocellular carcinoma, 378–382
- Genotyping, of hepatitis C virus. See *Hepatitis C virus, variants of*.
- Glomerulonephritis, in hepatitis C, treatment of, 482
- Growth-response genes, induction of, in liver regeneration, 342–344
- Health care workers, hepatitis B in, 253
 hepatitis C in, 260
- Hepadnaviruses, 251–252. See also *Hepatitis B virus*.
- Hepatic fibrogenesis. See *Fibrogenesis, hepatic*.
- Hepatitis, fibrosing cholestatic, hepatitis B virus variants in, 420
 fulminant, hepatitis B virus variants in, 419–420
- Hepatitis B, aflatoxin and, 255–256
 alcohol and. See *Alcohol, hepatitis B virus interactions with*.
 antigen-negative, 254
 carriers of, 252–253
 therapeutic vaccines for, 501
 chronic, definition of, 253–254
 cirrhosis in, 273–274
 interferons in, 471
 diseases associated with, 254–255
 epidemiology of, 252–253

- fibrogenesis in, 371-372
 geographic distribution of, 396
 hepatitis C coinfection with, hepatocellular injury in, 318-319
 hepatitis D coinfection with, 258, 455-456, 459-460
 interferons in, 472
 hepatocellular carcinoma in, 255, 395-406
 alcohol interaction in, 278-280, 292, 377, 388-390, 402
 carcinogenic mechanisms in, 494-495
 hepatitis C coinfection with, 401-402
 liver regeneration and, 327-328
 pathogenesis of, 493-494
 prevention of, 495-500
 hepatocellular injury in, 307-324
 animal models for, 309-310
 hepatitis C coinfection with, 318-319
 human leukocyte antigen expression and, 310-314
 interferon in, 311-314
 patterns of, 307-308
 viral antigens and, 314-317
 in liver transplantation, interferons in, 473
 incidence of, 252-253
 interferons in, 467-473
 clinical studies of, 468-471
 in Asians, 471-472
 in liver transplantation, 473
 nonresponders to, 472
 with cirrhosis, 471
 with hepatitis D, 472
 liver regeneration in. *See Liver, regeneration of.*
 persistence of, 253-254
 prevalence of, 252-253
 prevention of, 495-500
 serologic response in, 252
 transmission of, 253
 treatment of, 465-475
 drugs for, 473-475
 vaccines for, 495-500
 virus of. *See Hepatitis B virus.*
 Hepatitis B virus, alcohol interactions with. *See Alcohol, hepatitis B virus interactions with.*
 antibodies to, 252
 antigens of, in alcohol consumption, 276-278
 in chronic disease, 254
 in hepatocellular injury, 314-317
 in interferon therapy, 467-473
 variants of. *See Hepatitis B virus, variants of.*
 genes of, 252
 core, 407-409, 415-420
 envelope, 409, 415, 417-419
 hepatocellular carcinoma and, 397-400
 pre-core, 407-408, 415-420
 surface, 411, 413, 421-423
 X, 409, 411, 421
 in hepatitis D virus propagation, 451-452
 nomenclature of, 251-252
 structure of, 251-252
 variants of, 407-428
 clinical significance of, 415
 core genes, 407-409, 415-420
 enhancers and, 421
 hepatocellular injury and, 308
 in fibrosing cholestatic hepatitis, 420
 in fulminant hepatitis, 419-420
 interferon and, 419
 pre-core genes, 407-408, 415-420
 promoters and, 421
 small envelope proteins, 422-423
 surface genes, 411, 413, 421-423
 vaccines for, 500
 X gene, 409, 411, 421
 X antigen of, alcohol and, 275, 277, 279-280
 genes of, 409, 411, 421
 Hepatitis C, alcohol and. *See Alcohol, hepatitis C virus interactions with.*
 carriers of, therapeutic vaccines for, 501
 cirrhosis in, 273-274
 diseases associated with, 263-264
 fibrogenesis in, 371-372
 hepatitis D coinfection with, 460
 hepatocellular carcinoma in, 400-403
 alcohol interaction in, 280-281, 292, 377, 388-390, 402-403
 carcinogenic mechanisms in, 494-495
 hepatitis B coinfection with, 401-402
 liver regeneration and, 327-328
 pathogenesis of, 493-494
 prevention of, 495, 500-501
 hepatocellular injury in, 307-324
 hepatitis B coinfection with, 318-319
 mediators in, 317-318
 patterns of, 307-308
 interferons in, clinical studies of, 476-481
 in liver transplantation, 483
 with extrahepatic manifestations, 481-482
 liver generation in. *See Liver, regeneration of.*
 prevention of, 495, 500-501
 transmission of, 261-263
 treatment of, 444, 446, 475-485
 drugs for, 483-484
 vaccines for, 500-501
 virus of. *See Hepatitis C virus.*
 Hepatitis C virus, alcohol interactions with. *See Alcohol, hepatitis C virus interactions with.*
 antigens of, in interferon therapy, 476

- Hepatitis C virus (*Continued*)
 burden of, 260-261
 detection of, 259-260
 genes of, 258-259
 genotypes of. See *Hepatitis C virus, variants of*.
 nomenclature of, 258-259
 quasispecies behavior of, 439-446
 structure of, 258-259
 variants of, 429-449
 clinical significance of, 434-436
 genesis of, 437-439
 hepatocellular injury and, 308
 identification methodology for, 432-434
 maintenance of, 437-439
 multiple infections with, 436
 nomenclature of, 432-434
 quasispecies behavior of, 439-446
 RNA polymerase fidelity and, 440-441
- Hepatitis D, alcohol and, 258, 460
 chronic, 257-258
 clinical features of, 456
 diseases associated with, 258
 epidemiology of, 257
 genes of, 459
 hepatitis B coinfection with, 258, 451-452, 455-456, 459-460
 interferons in, 472
 hepatitis C coinfection with, 460
 HIV infection with, 460
 incidence of, 257
 mechanisms of, 455-457
 natural history of, 455-456
 pathogenesis of, 456-460
 patterns of, 457
 prevalence of, 257
 prognosis for, 457-460
 serologic response in, 256-257
 transmission of, 257
 virus of. See *Hepatitis D virus*.
- Hepatitis D virus, 451-464
 antibodies to, 256-257
 antigens of, 256-257
 classification of, 451-452
 genes of, 256, 453-455
 nomenclature of, 256
 replication of, 452-453
 structure of, 256, 451-452
- Hepatitis delta. See *Hepatitis D*.
- Hepatocellular carcinoma, 395-406
 chemical carcinogens in, 377-394
 alcohol, 378, 386-390
 genotoxic, 378-382
 nodule pathology and, 384-386
 nongenotoxic, 383
 geographic distribution of, 396
 in hepatitis B, 255, 395-400
 alcohol interaction in, 278-280, 292, 377, 388-390, 402
 carcinogenic mechanisms in, 494-495
 hepatitis C coinfection with, 401-402
 liver regeneration and, 327-328
 pathogenesis of, 493-494
 prevention of, 495-500
 in hepatitis C, 263-264, 400-403
 alcohol interaction in, 280-281, 292, 377, 388-390, 402-403
 carcinogenic mechanisms in, 494-495
 hepatitis B coinfection with, 401-402
 liver regeneration and, 327-328
 pathogenesis of, 493-494
 prevention of, 495, 500-501
 prevention of, hepatitis vaccines for, 493-505
 resistance phenotype in, 380-382
- Hepatocyte(s), carcinoma of. See *Hepatocellular carcinoma*.
 injury of, in hepatitis B, 307-324
 animal models for, 309-310
 hepatitis C coinfection with, 318-319
 human leukocyte antigen expression and, 310-314
 interferon in, 311-314
 patterns of, 307-308
 viral antigens and, 314-317
 in hepatitis C, 307-324
 hepatitis B coinfection with, 318-319
 mediators in, 317-318
 patterns of, 307-308
 regeneration of. See *Liver, regeneration of*.
- Hepatocyte growth factor, in liver regeneration, 328-330
- HIV infection. See *Human immunodeficiency virus infection*.
- Human immunodeficiency virus infection, hepatitis C coinfection with, 261-262
 hepatitis D coinfection with, 460
- Human leukocyte antigens, hepatocellular injury from, in hepatitis, 310-314
- Immune response, in hepatocellular injury, in hepatitis, 307-308, 311-318
- Immunodeficiency, mild, in alcohol consumption, 275
- Immunotherapy, for hepatitis B, 475
- Indomethacin, in hepatitis C, 484
- Injury, hepatocellular. See *Hepatocyte(s), injury of*.
- Interferons, 465-491
 administration of, 466-467
 in hepatic fibrogenesis inhibition, 368
 in hepatitis B, 467-473
 clinical studies of, 468-471
 core gene mutants and, 419
 endogenous, 311-314
 in Asians, 471-472

- in liver transplantation, 473
- nonresponders to, 472
- with cirrhosis, 471
- with hepatitis D, 472
- in hepatitis C, 435
 - clinical studies of, 476-481
 - in liver transplantation, 483
 - with extrahepatic manifestations, 481-482
- in liver regeneration, 332-333
- nonresponders to, 472
- side effects of, 467
- types of, 466
- Interleukins, in alcohol consumption, liver regeneration and, 295-296
 - in liver regeneration, 352
- Iron reduction therapy, in hepatitis C, 484

- Ketoprofen, in hepatitis C, 484

- Laminin, in liver, 362-363
- Lamivudine, in hepatitis B, 474-475
- Leukocytes, polymorphonuclear, in hepatic extracellular matrix degradation, 365
- Liver, alcohol metabolism in, 275
 - alcoholic disease of, hepatitis virus interactions in. See *Alcohol, hepatitis B (or C) interactions with.*
 - fibrogenesis of. See *Fibrogenesis, hepatic.*
 - necrosis of, regeneration in, 326-327
 - nodules in, carcinoma development from, 379-380, 384-386
 - regeneration of, 325-339, 341-360
 - alcohol effects on, 293
 - cytokines and, 295-297
 - receptor-mediated responses in, 297-299
 - cytokines in, 295-297, 328-333, 351-354
 - epithelial cells in, 326-328
 - extracellular matrix in, 333-334
 - functional maintenance during, 345-347
 - hepatocyte growth factor in, 328-330
 - in cirrhosis, 355
 - in hepatitis, 354
 - in transplantation, 354-355
 - interferons in, 332-333
 - primary growth-response gene induction in, 342-344
 - transcription factor activation in, 347-351
 - transforming growth factors in, 330-332
 - tumor necrosis factor in, 331
- transplantation of, hepatitis B in, interferon in, 473
- hepatitis C in, treatment of, 483
- regeneration in, 354-355

- Malnutrition, in alcohol abuse, hepatocellular sensitivity to, 292
- Metalloproteinases, in hepatic extracellular matrix degradation, 365

- Necrosis, liver, regeneration in, 326-327
- Neonates, hepatitis B transmission to, 253
- Nodules, hepatic, carcinoma development from, 379-380, 384-386
- Nongenotoxic carcinogens, in hepatocellular carcinoma, 383
- Nuclear factor kappa B, activation of, in liver regeneration, 349-351
- Nutrition, in alcohol abuse, hepatocellular sensitivity to, 292

- Oval cells, in liver regeneration, 326-327

- Pencyclovir, in hepatitis B, 474
- Perlecan, in liver, 363
- Peroxisome proliferators, in hepatocellular carcinoma, 383
- Phagocytosis, in hepatic extracellular matrix degradation, 365
- Phlebotomy, in hepatitis C, 484
- Plasmin, in hepatic extracellular matrix degradation, 365
- Platelet-derived growth factor, in stellate cell proliferation, 368-369
- Polymerase, in hepatitis B, hepatocellular injury from, 317
- Polymerase chain reaction, in hepatitis C virus detection, 259-260
 - in hepatitis C virus genotyping, 433-434
- Pregenome, of hepatitis B virus gene, 409
- Prostaglandin(s), in hepatic fibrogenesis inhibition, 368
 - in stellate cell proliferation, 369-370
- Prostaglandin E, in hepatitis B, 474
- in hepatitis C, 483-484
- Proteinases, in hepatic extracellular matrix degradation, 365
- Proteoglycans, in liver, 363-364

- Quasispecies swarm, of hepatitis C virus, 439-446

- Regeneration, of liver cells. See *Liver, regeneration of.*

- Ribavirin, in hepatitis C, 484
RNA polymerase, in hepatitis C virus replication, 440-444
- Saliva, hepatitis C virus in, 262
Secreted protein acidic and rich in cysteine (SPARC), in liver, 363
Signal transduction, in liver cell regeneration, alcohol effects on, 293
Signal transduction and activator of transcription (stat3), activation of, in liver regeneration, 351
SPARC, in liver, 363
Stat3 (signal transduction and activator of transcription), activation of, in liver regeneration, 351-352
Stellate cells, function of, 366
proliferation of, 366-370
Stromelysins, in hepatic extracellular matrix degradation, 365
Syndecans, in liver, 363-364
- T lymphocytes, in hepatocellular injury, in hepatitis, 314-315, 318
Tenascins, in liver, 363
Transcription factors, activation of, in liver regeneration, 347, 349
Transforming growth factors, in hepatic fibrogenesis, 367
in liver regeneration, 330-332
in stellate cell proliferation, 368-369
Transplantation, liver, hepatitis B in, interferon in, 473
hepatitis C in, treatment of, 483
regeneration in, 354-355
Tumor necrosis factors, in alcohol consumption, 275-276, 295-297
liver regeneration and, 295-297, 299-301
in hepatitis B, 311, 314
in liver regeneration, 331
- Undulin, in liver, 363
Ursodeoxycholic acid, in hepatitis C, 484
- Vaccines, for hepatitis B, 495-500
for hepatitis C, 500-501
- Woodchuck hepatitis virus, 310
- X antigen, of hepatitis B virus, alcohol and, 275, 277, 279-280
as carcinogen, 494
gene of, 409, 411, 421
in hepatocellular injury, 316-317